OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Receives Average Rating of “Hold” from Brokerages

Shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) have been assigned an average recommendation of “Hold” from the five ratings firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $5.6667.

Several brokerages recently issued reports on OKYO. HC Wainwright dropped their price objective on OKYO Pharma from $7.00 to $5.00 and set a “buy” rating on the stock in a research note on Monday, July 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of OKYO Pharma in a research report on Tuesday, April 21st.

OKYO Pharma Price Performance

Shares of NASDAQ:OKYO opened at $1.43 on Monday. The firm’s 50 day simple moving average is $1.59 and its 200-day simple moving average is $1.76. OKYO Pharma has a one year low of $1.34 and a one year high of $3.35.

Hedge Funds Weigh In On OKYO Pharma

Institutional investors have recently made changes to their positions in the company. Citadel Advisors LLC bought a new stake in shares of OKYO Pharma in the third quarter valued at about $31,000. XTX Topco Ltd bought a new position in OKYO Pharma during the 4th quarter worth about $36,000. Finally, Renaissance Technologies LLC grew its holdings in OKYO Pharma by 235.0% during the 4th quarter. Renaissance Technologies LLC now owns 138,000 shares of the company’s stock worth $286,000 after acquiring an additional 96,800 shares in the last quarter. Hedge funds and other institutional investors own 2.97% of the company’s stock.

About OKYO Pharma

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.